Ridgeline Therapeutics

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Be bold! Developing transformative drugs to reverse muscle aging and obesity-linked NASH.

Ridgeline is developing oral drugs to reverse age-related muscle degeneration (e.g., sarcopenia), delay muscle degeneration in disease states (e.g., Duchenne muscular dystrophy), and undo liver fibrosis in obese patients with NASH (non-alcoholic steatohepatitis). Leading clinical candidates are completing GMP scale-up and GLP safety/toxicity studies. Second-generation leads (e.g., increased potency) are completing multi-species PK characterization and dose-ranging efficacy studies.
Company Type:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
NASH
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Ridgeline Therapeutics